Endothelial Microparticles Induce Inflammation in Acute Lung Injury

Background

Previously, we have shown that endothelial microparticles (EMPs) injected into mice induce acute lung injury (ALI) [1]. In this study, we hypothesize that EMPs induce ALI by initiating cytokine release in the lung, leading to recruitment and activation of neutrophils.

Materials and methods

C57BL/6J male mice (8–10 wk old) were intravenously injected with EMPs (200,000/mL), LPS (2 mg/kg), or both. Bronchoalveolar lavage (BAL) and serum levels of IL-1β and TNF-α were analyzed by enzyme-linked immunoassay (ELISA). Morphometric analysis was performed on H and E stained lung sections. Myeloperoxidase (MPO) levels were determined via an enzymatic assay and immunofluorescence of stained sections.

Results

EMPs led to significantly increased pulmonary and systemic IL-1β and TNF-α levels, which correlated with increased neutrophil recruitment to the lung. MPO levels in the lungs were increased significantly following injection of EMPs or LPS, compared to PBS. In mice treated with EMPs and LPS either simultaneously or successively, the cytokine and MPO levels were significantly increased over that of either treatment alone.

Conclusion

EMPs contribute to lung injury through the initiation of a cytokine cascade that increases recruitment of neutrophils and subsequent release of MPO. Furthermore, treatment of mice with both EMPs and LPS induced greater lung injury than either treatment alone, suggesting that EMPs prime the lung for increased injury by other pathogens. Therapies aimed at reducing or blocking EMPs may be a useful strategy for attenuating lung injury.

Introduction

Microparticles (MPs) are submicron vesicles that are released from activated or apoptotic cells, and elevated levels have been correlated with several human disease states such as sickle cell disease, diabetes, and atherosclerosis 2, 3, 4, 5, 6, 7, 8, 9. Recently, tissue factor-positive microparticles (TF-MPs) were shown to be elevated in the bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome (ARDS) [10]. This study implied that TF-MPs are released by activated alveolar epithelium, but also suggests that microparticles may be distributed to the lung and traverse the respiratory barrier. Endothelial microparticles (EMPs) are a subgroup of MPs that are shed from the endothelium in response to a variety of stimuli, including lipopolysaccharide (LPS), autoantibodies, and cytokines such as interlukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) [11]. EMPs have been show to be significantly increased in human disease states in comparison to the other subgroups of microparticles, which include erythrocyte, white blood cell, and platelet MPs 2, 3, 4, 5, 6, 7, 8, 9. Additionally, EMPs have been shown to alter endothelial function in many of these pathologies, implying a role as an injurious agent. Previously, we have shown that EMPs contribute to acute lung injury in a murine model. This conclusion was based on multiple measures of histologic parameters, lung permeability indices, and dysregulation of endothelial nitric oxide formation and release [1].

While several published studies exist quantifying EMPs in human disease and suggesting that they would serve as a worthy biomarker, the mechanisms by which EMPs initiate and propagate disease are still not well understood. In an attempt to further characterize the role of EMPs in lung injury, we investigated their effects on the pulmonary and systemic inflammatory cascade. Cytokines IL1-β and TNF-α have been studied as predictors of survival in ARDS [12]. While their release may be from multiple cell types (i.e., epithelium, monocytes, and macrophages), neutrophils are a large source of these cytokines. As a measure of neutrophil activation in this setting, it implicates neutrophils and serves as a source of further oxidative injury in acute lung injury (ALI).

In human disease with associated ALI/ARDS, there are often multiple pathogenic steps. To explore the possibility that EMPs “prime” the lung for more extensive injury by other pathogens, we explored their effect on cytokine and myeloperoxidase production in a two-hit model of injury using EMPs and lipopolysaccharide (LPS). We reasoned that if EMPs set up the lung for increased damage, the possibility is raised that therapies aimed at preventing release or reducing EMP binding in the lung could play a protective role in reducing the lung injury that accompanies several human disease states.